Clinical Trials Arena on MSN3d
First subject enrolled in MUSC Hollings’ Phase II/III trial of HNSCC treatmentHollings Cancer Center, US, has enrolled the first subject in the Phase II/III FORTIFI-NH01 trial of ficerafusp alfa to treat ...
MedPage Today on MSN10d
Better Response, Survival in Head and Neck Cancer With Dual Pre-Op ImmunotherapyTwo neoadjuvant immunotherapy combinations for head and neck cancer substantially increased the response rate versus a single ...
Head and neck squamous cell carcinomas responded better to a combination of two immunotherapies than to one immunotherapy drug, according to a study in Cancer Cell. In addition, an analysis of the ...
indicating the potential of targeted CRISPR-LNP delivery systems for cancer treatment. Head and neck squamous cell carcinomas (HNSCC) are localized solid cancers that originate in the upper ...
To leverage and implement these important findings, two Phase 1 "window" trials, one enrolling patients with HPV+ cervical cancer and the other with HPV+ HNSCC, will soon launch at UH Seidman ...
[85,86] The EORTC is now planning a randomized Phase III study [107] in patients with locally advanced HPV/p16-negative HNSCC tumors with or without the hypoxic cell radiosensitizer nimorazole in ...
Initiated Phase 1/2 combination study of micvotabart pelidotin and Merck’s anti-PD-1 therapy, KEYTRUDA ® (pembrolizumab), in patients with R/M HNSCC and other advanced solid tumors. We aim to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback